InterCure Ltd
TASE:INCR
Gross Margin
InterCure Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IL |
I
|
InterCure Ltd
TASE:INCR
|
281.3m ILS |
30%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
605.4B USD |
83%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
415.6B USD |
68%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
196B CHF |
74%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
171.9B GBP |
82%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
186.3B CHF |
76%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
84%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
202B USD |
78%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.4B USD |
68%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
140.1B USD |
74%
|
InterCure Ltd
Glance View
InterCure Ltd. engages in the business of medical cannabis and biomedicine. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on InterCure Ltd's most recent financial statements, the company has Gross Margin of 30.5%.
You don't have any saved screeners yet